Epizyme, Inc.
EPZMDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Tazemetostat
Diffuse Large B-cell Lymphoma (DLBCL)
Prednisolone
B-cell Lymphomas (Phase 1)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tazemetostat | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
Prednisolone | Phase 2 | B-cell Lymphomas (Phase 1) | - | - |
Diffuse Large B-cell Lymphoma (DLBCL)
1 drug in this indication
B-cell Lymphomas (Phase 1)
1 drug in this indication
Relapsed/Refractory Follicular Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Epizyme, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Epizyme, Inc.'s (EPZM) pipeline across Phase 3, Phase 2. Its lead program is Tazemetostat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Epizyme, Inc.'s next FDA catalyst?→
Epizyme, Inc.'s (EPZM) next tracked catalyst is a Phase 3 expected February 13, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EPZM biotech catalysts?→
Add EPZM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Epizyme, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.